[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neurosense Therapeutics Ltd (NRSN)

Neurosense Therapeutics Ltd (NRSN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,936
  • Shares Outstanding, K 32,557
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,130 K
  • EBIT $ -3 M
  • EBITDA $ -11 M
  • 60-Month Beta 1.56
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.54
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 06/30/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6701 +2.52%
on 06/15/26
0.9300 -26.13%
on 05/28/26
-0.1396 (-16.89%)
since 05/15/26
3-Month
0.6300 +9.05%
on 03/24/26
1.0500 -34.57%
on 03/16/26
-0.1724 (-20.06%)
since 03/13/26
52-Week
0.6300 +9.05%
on 03/24/26
2.5199 -72.74%
on 06/20/25
-1.6930 (-71.13%)
since 06/13/25

Most Recent Stories

More News
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

CAMBRIDGE, Mass. , June 11, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"  or the "Company"), a late-clinical stage biotechnology company developing novel...

NRSNW : 0.1100 (-38.79%)
NRSN : 0.6870 (-6.56%)
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patents

NRSNW : 0.1100 (-38.79%)
NRSN : 0.6870 (-6.56%)
NeuroSense Announces Pricing of Insider-Led PIPE Financing

Financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing significant shareholder

NRSN : 0.6870 (-6.56%)
NeuroSense Granted Brazilian Patent Covering PrimeC Composition

CAMBRIDGE, Mass. , April 6, 2026 /PRNewswire/ --  NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel...

NRSN : 0.6870 (-6.56%)
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements

CAMBRIDGE, Mass. , April 3, 2026 /PRNewswire/ --  NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments...

NRSNW : 0.1100 (-38.79%)
NRSN : 0.6870 (-6.56%)
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

CAMBRIDGE, Mass. , March 31, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments...

NRSN : 0.6870 (-6.56%)
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout

CAMBRIDGE, Mass. , March 24, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...

NRSN : 0.6870 (-6.56%)
PrimeC New Data to Be Presented at AD/PDâ„¢ 2026 Conference

Dr. Christian Lunetta to Present "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial"

NRSNW : 0.1100 (-38.79%)
NRSN : 0.6870 (-6.56%)
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower functional...

NRSNW : 0.1100 (-38.79%)
NRSN : 0.6870 (-6.56%)
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

CAMBRIDGE, Mass. , March 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...

NRSNW : 0.1100 (-38.79%)
NRSN : 0.6870 (-6.56%)

Business Summary

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company. It focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, such as ALS, Alzheimer's and Parkinson's disease. NeuroSense Therapeutics Ltd. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 0.8479
2nd Resistance Point 0.8089
1st Resistance Point 0.7480
Last Price 0.6870
1st Support Level 0.6481
2nd Support Level 0.6091
3rd Support Level 0.5482

See More

52-Week High 2.5199
Fibonacci 61.8% 1.7980
Fibonacci 50% 1.5749
Fibonacci 38.2% 1.3519
Last Price 0.6870
52-Week Low 0.6300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.